Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 5-Year Yield-on-Cost % is 18.33 as of Jul. 21, 2026, which is 28% above its 10-year median of 14.27. GuruFocus rates CPHGF with a GF Scoreâ„¢ of 55/100 and a GF Valueâ„¢ of $0.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 513 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 95.32% on this metric.
The historical rank and industry rank for Consun Pharmaceutical Group's 5-Year Yield-on-Cost % or its related term are showing as below:
CPHGF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.4 Med: 14.27 Max: 36.05
Current: 18.33
During the past 13 years, Consun Pharmaceutical Group's highest Yield on Cost was 36.05. The lowest was 2.40. And the median was 14.27.
CPHGF's 5-Year Yield-on-Cost % is ranked better than 95.32% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs CPHGF: 18.33
Consun Pharmaceutical Group (OTCPK:CPHGF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Consun Pharmaceutical Group 5-Year Yield-on-Cost % Related Terms
CPHGF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's 5-Year Yield-on-Cost % falls into.
Consun Pharmaceutical Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Consun Pharmaceutical Group (CPHGF) has a 5-Year Yield-on-Cost % of 18.33 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Consun Pharmaceutical Group and its competitors. This is 28% above median its historical median of 14.27. Over the past decade, Consun Pharmaceutical Group's 5-Year Yield-on-Cost % has ranged from 2.40 to 36.05. According to the industry distribution chart, Consun Pharmaceutical Group ranks #24 out of 513 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is Consun Pharmaceutical Group's 5-Year Yield-on-Cost % too high?
Consun Pharmaceutical Group's current 5-Year Yield-on-Cost % of 18.33 is 28% above median its 10-year median of 14.27. Over the past 10 years, this metric has ranged from a low of 2.40 to a high of 36.05. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Consun Pharmaceutical Group's value of 18.33 is 700.4% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #24 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #24 out of 513 companies for 5-Year Yield-on-Cost %. This places Consun Pharmaceutical Group in the top 5% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.29. Consun Pharmaceutical Group's value of 18.33 is 700.4% above this benchmark. Historically, Consun Pharmaceutical Group's own 5-Year Yield-on-Cost % has ranged from 2.40 to 36.05 over the past decade. While the company's 10-year median is 14.27 vs. the industry median of 2.29, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current 5-Year Yield-on-Cost % of 18.33 is 700.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current 5-Year Yield-on-Cost % is 18.33, which is 28% above median its own 10-year median of 14.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.80 — trading 200% above its estimated fair value. The current 5-Year Yield-on-Cost % is 18.33, which is 28% above median its 10-year median of 14.27 and 700.4% above the Drug Manufacturers industry median of 2.29. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current 5-Year Yield-on-Cost % is 18.33 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 200% above its estimated GF Value™ of $0.60.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
5-Year Yield-on-Cost %: 18.33 (28% above median its 10-year median of 14.27)
GF Value™: $0.60 vs. price of $1.80 (200% above fair value)
Industry Position: 700.4% above the Drug Manufacturers median (#24 of 513)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
